

- Giant cell arteritis (temporal arteritis), 2188  
 as cause of fever of unknown origin, 138, 141  
 clinical features of, 108, 2188  
 aortic aneurysm, 386e-4f, 1638  
 aortitis, 1642  
 headache, 108  
 ocular, 202, 202f, 2188  
 oral pain, 239  
 definition of, 2188  
 diagnosis of, 2188–2189  
 arteriogram, 386e-4f  
 erythrocyte sedimentation rate, 108  
 temporal artery biopsy, 386e-6f, 2188–2189  
 incidence and prevalence of, 2188  
 ischemic stroke in, 2567  
 pathogenesis of, 1638, 2188  
 treatment of, 141, 2189
- Giant cell myocarditis, 1561–1562
- Giant cell tumor, 119e-3, 609t
- Giant melanocytic nevus, 493
- Giardia* spp., 245e-4t, 1405–1406, 1405f
- Giardia* spp. infections, 1405  
 clinical features of, 152e-4t, 266t, 1406  
 acute disease, 266  
 chronic disease, 269, 797  
 diagnosis of, 152e-4t  
 alternative procedures, 245e-5t  
 blood and tissue, 245e-4t  
 duodenal content analysis, 245e-1  
 laboratory tests, 245e-4t  
 serologic and molecular tests, 245e-6t, 267  
 small-intestinal mucosal biopsies, 1939, 1941f  
 stool analysis, 1406, 1406t  
 differential diagnosis of, 266t  
 epidemiology of, 266, 855, 1405–1406  
 incubation period for, 152e-4t  
 pathogenesis of, 1406  
 prevention of, 1407  
 in returning war veterans, 152e-8  
 in travelers, 855t  
 treatment of, 152e-4t, 1406  
 albendazole, 1406  
 furazolidone, 246e-9  
 metronidazole, 268, 1406  
 nitazoxanide, 246e-11, 1406  
 quinacrine, 246e-12  
 tinidazole, 246e-13
- Gibbus, 1110
- Giemsa stain, 83e-1, 245e-2, 342
- Gigantism. *See* Acromegaly
- Gilbert's syndrome, 2002  
 clinical features of, 282, 2002–2003, 2003t  
 diagnosis of, 1995, 1996f, 1998t, 2003t  
 drug sensitivity in, 103e-13  
 genetic considerations in, 40, 282, 2002–2003  
 unconjugated bilirubin in, 280
- GINA (Genetic Information Nondiscrimination Act), 101e-6, 445, 449, 480e-6
- GI-NETs. *See* Gastrointestinal neuroendocrine tumors (GI-NETs)
- Ginger, 261, 404t, 1880
- Gingival erythema, linear, 237
- Gingival fibromatosis, idiopathic familial, 237
- Gingival hyperplasia, 237
- Gingival hypertrophy (epulis), 46e-2f
- Gingival recession, 46e-4f
- Gingivitis  
 acute necrotizing ulcerative (Vincent's angina), 231, 233, 236, 238t, 1097  
 clinical features of, 46e-3f, 46e-4f, 236  
 etiology of, 1097  
 prevention of, 423  
 as risk factor for pneumonia, 805
- Gingivostomatitis, herpetic. *See* Herpes simplex virus (HSV) infections, oral-facial
- Ginkgo biloba*, 404t, 2547t, 2602
- Ginseng, 63, 404t
- GIRK4 channels, 306
- GIST. *See* Gastrointestinal stromal tumor (GIST)
- Gitelman's syndrome  
 clinical features of, 306, 332e-8  
 diagnosis of, 306, 307  
 differential diagnosis of, 321  
 genetic considerations in, 306, 332e-7t, 332e-8, 2461
- GJB2* gene mutations, 220
- Glanders, 1045t, 1049
- Glanzmann's thrombasthenia, 730
- Glasgow Coma Scale, 457e-5, 457e-5t, 1730t, 1777
- Glucocorticoids, 2668–2669, 2669t
- Glaucoma  
 acute angle-closure, 200, 205  
 clinical features of, 205  
 headache in, 108  
 low-tension, 205  
 pathophysiology of, 204–205, 205f  
 treatment of, 205  
 visual field assessment in, 197–199  
 visual loss in, 204–205
- Gleason grading system, for prostate cancer, 582
- Gliadin, 373e-7
- Glial-derived neurotrophic factor (GDNF), 444e-7
- Glibornuride, 2414t
- Gliclazide, 2414t
- Glimepiride, 2413, 2414t
- Glioblastoma(s), 440e-9f, 599, 600, 600f, 601f
- Glioblastoma multiforme, 91e-4
- Gliomas  
 brainstem, 441e-39f, 601  
 cerebral, 440e-9f  
 EEG in, 442e-1f  
 genetic considerations in, 101e-2t  
 hypothalamic, 2264  
 imaging in, 2262  
 ocular signs in, 198  
 optic, 2264
- Gliomatosis cerebri, 600
- Gliosarcomas, 601
- Glipizide, 34t, 40, 2413, 2414t
- Gliquidone, 2414t
- Global aphasia, 177t, 178
- Global burden of disease. *See* Global health
- Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010), 9, 761
- Global Fund to Fight AIDS, Tuberculosis, and Malaria, 8
- Global health, 7. *See also* Low- and middle-income countries  
*A. baumannii* infections, 1036, 1037  
 acyclovir effectiveness, 1183  
 addressing problems in, 17–18  
 alcoholic liver disease, 2052  
 alcohol use disorder, 2726, 2728  
 amebiasis, 1363  
 angiostrongyliasis, 1412  
 antibiotic resistance, 966, 1101  
 aplastic anemia, 663  
 aspergillosis, 1345, 1346t  
 ataxias, 2631  
 azithromycin resistance, 233  
*B. mallei* infections, 1049  
*B. pseudomallei* infections, 1048  
*Babesia* infections, 1384, 1385f  
*Bartonella* infections, 1082  
 biomass smoke-induced illness, 1693–1694, 1694f  
 bioterrorism, 918  
 blastomycosis, 1337  
 botulism, 987  
 brain abscess, 900  
 brain drain, 13–14  
 bronchiectasis, 1695  
*Brucella* infections, 194e-1  
*C. difficile* infections, 859  
*C. jejuni* infections, 1059  
*C. trachomatis* infections, 1167  
 cancer, 16, 16f, 467–468, 472f, 490  
*Candidatus* *Neoehrlichia mikurensis* infection, 1160  
 cardiac transplantation, 1516  
 cardiovascular disease, 15–16, 266e-2–3, 266e-3f, 266e-3t  
 Carrión's disease, 1083  
 cervical cancer, 595, 1198  
 cholera, 1061–1062, 1062f  
 chronic fatigue syndrome, 464e-1  
 chronic kidney disease, 1821, 1822, 1825  
 chronic myeloid leukemia, 694–695, 694f  
 cirrhosis, 2059–2060  
 climate change and. *See* Climate change  
 clostridial infections, 990  
 congenital syphilis, 1136  
 cryptococcosis, 1339, 1341  
 cryptosporidiosis, 1407  
 cystic fibrosis, 1700  
 diabetes mellitus, 15, 266e-4, 2400, 2400f  
 dietary assessment, 95e-6  
 diphtheria, 977, 979  
 disease burden  
 causes of, 10f, 11t  
 health workforce and, 13e-4f  
 by income, 13e-2f, 93e-5f, 93e-5t  
 mortality and, 9, 11t, 266e-2f  
 by region, 11t, 93e-5f, 93e-5t  
 risk factors, 9–10  
 disease eradication, 785  
 disorders of sex development, 2357  
 donovansiosis, 198e-1  
 drug hypersensitivity, 378  
 EBV infections, 1187  
 economics of, 8, 9  
 encephalitis, 896  
 endemic treponematoses, 207e-1, 207e-1f  
 endemic typhus, 1158–1159  
 enteric (typhoid) fever, 1050, 1050f, 1052  
 enteritis necroticans, 991  
 enterococcal infections, 973  
 enterovirus infections, 1290, 1292  
 epidemic typhus, 1158  
 epidemiologic transition, 266e-1–2  
 esophageal cancer, 532  
 familial hypercholesterolemia, 2441  
 fatigue, 152  
 fever of unknown origin, 136, 136t  
 field experiences in, ethical issues in, 17e-3  
 flea-borne spotted fever, 1158  
 fungal meningitis, 898  
 gastric adenocarcinoma, 534  
 genomics and, 445, 778  
 glucose-6-phosphate dehydrogenase deficiency, 655, 655f  
 glycogen storage diseases, 433e-5  
 gnathostomiasis, 1412  
 gonococcal infections, 1003, 1004  
 gram-negative bacterial infections, 1026–1027  
 group *A Streptococcus* infections, 233, 964, 964f  
*H. influenzae* infections, 1010, 1012  
*H. pylori* infection, 1042  
 HBV infection, 2060  
 HCV infection, 2059–2060  
 head and cancer, 502  
 heart failure, 1500–1501, 1516  
 heavy metal poisoning, 472e-1, 472e-3  
 helminthic infections, 255e-2  
 hemoglobinopathies, 633  
 hepatitis E infections, 1991  
 hepatocellular carcinoma, 544–545, 544t  
*HFE* gene mutations, 2519  
 HHV-6 infections, 1194  
 HHV-8 infections, 1194  
 histoplasmosis, 1332  
 HIV infection, 12, 12f, 13f, 1219–1220, 1220f, 1223–1225, 1224f  
 HPV infection, 1198  
 HSV infection, 1176  
 HTLV-1 infections, 225e-4, 225e-4f  
 HTLV-2 infections, 225e-5–6  
 human granulocytotropic anaplasmosis, 1160  
 hyperlipidemia, 266e-4  
 hyperparathyroidism, 315  
 hypersensitivity pneumonitis, 1683  
 hypertension, 266e-4  
 hyponatremia, 2283  
 infectious disease-associated  
 glomerulonephritis, 1847–1850  
 inflammatory bowel disease, 1947  
 inflammatory myopathies, 2197  
 influenza, 1209, 1210